An unusual cause of jaundice in a patient with breast cancer
Abstract
A 48-year old woman with metastatic breast cancer and extensive bone marrow infiltration was admitted with extreme lethargy, jaundice and deranged liver function tests. She had been started on anastrozole in May 2013 for bony metastases, detected on a bone scan. A CT scan performed at that time had shown no evidence of metastatic or nodal disease elsewhere. Over the subsequent 2 months, the patient had become progressively jaundiced. Outpatient abdominal ultrasound and CT liver had shown a fatty liver with no focal lesions. She was admitted in August 2013 with bilirubin 567, alkaline phosphatase 385, alanine aminotransferase 98, albumin 25 and international normalised ratio 1.9. The patient ultimately had a liver biopsy, which demonstrated features of drug-induced steatohepatitis, and anastrozole was found to have been the probable cause. This case explores the differentials of jaundice in a patient with cancer and describes a rare cause of drug-induced liver injury.
ANA, antinuclear antibody; CMV, cytomegalovirus; EBNA, Epstein-Barr nuclear antigen.
Footnotes
Contributors: The case report was written by RL. AE had an advisory/editorial role prior to final submission.
Competing interests: None.
Patient consent: Obtained.
Provenance and peer review: Not commissioned; externally peer reviewed.
References
- 1. Buzdar A, Howell A, Cuzick J, et al; Arimidex, Tamoxifen, Alone or in Combination Trialists’ Group. Comprehensive side-effects profile of anastrazole and tamoxifen as adjuvant treatment for early-stage breast cancer: long term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633–43. 10.1016/S1470-2045(06)70767-7 [] [[PubMed][Google Scholar]
- 2. Inno A, Basso M, Vecchio F et al. Anastrozole-related acute hepatitis with autoimmune features: a case report. BMC Gastroenterology 2011;11:32 10.1186/1471-230X-11-32 ] [[Google Scholar]
- 3. de La Cruz L, Romero-Vazquez J, Jimenez-Saenz M et al. Severe acute hepatitis in a patient treated with anastrozole. Lancet 2007;369:23–24. 10.1016/S0140-6736(07)60017-8 [] [[PubMed][Google Scholar]
- 4. Zupata E, Zubiaurre L, Bujanda L et al. Anastrazole-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2006;18:1233–4. 10.1097/01.meg.0000243868.64078.af [] [[PubMed][Google Scholar]
- 5. Office of National Statistics: Breast Cancer in England 2010.
- 6. .[PubMed]
- 7. Chalasani NP, Hayashi PH, Bonkovsky HL et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950–66. 10.1038/ajg.2014.131 [] [[PubMed][Google Scholar]
- 8. Stravitz R, Sanyal A Drug-induced steatohepatitis. Clin Liver Dis 2003;7:435–51. 10.1016/S1089-3261(03)00027-8 [] [[PubMed][Google Scholar]
- 9. Kamdem L, Liu Y, Stearns V et al. In vitro and in vivo oxidative metabolism and glucuronidation of anastrazole. Br J Clin Pharmacol 2010;70:854–69. 10.1111/j.1365-2125.2010.03791.x ] [[Google Scholar]
- 10. Kapucuoglu N, Coban T, Raunio H et al. Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Lett 2003;202:17–23. 10.1016/j.canlet.2003.08.015 [] [[PubMed][Google Scholar]